Affymetrix, Inc. (NASDAQ: AFFX) and PathGEN Dx Pte. Ltd., a
spin-off molecular diagnostics company founded by researchers from
the Genome Institute of Singapore, today announced they have signed
a Powered by AffymetrixTM (PbA) Program agreement.
Under this PbA agreement, PathGEN Dx will develop an in-vitro
diagnostic kit for comprehensive pathogen detection using their
PathGEN® PathChip and is based on a patented, efficient, and
accurate microarray-based protocol and analysis method. The kit
will be comprised of PathGEN Dx’s proprietary reagents, an
automated software package, and a contract manufactured GeneChip®
microarray from Affymetrix. It will detect the presence of more
than 70,000 viral and bacterial genomes from a wide variety of
human samples, annotate the genomic information, and identify
co-infecting pathogens.
Dr. Martin Hibberd, PathGEN Dx Co-Founder, said, “This will be
the start of our development plan for a diagnostic microarray that
we feel will ultimately help medical researchers and surveillance
investigators identify the full range of viruses and bacteria in
their samples.”
“We are very pleased to have PathGEN Dx join the Affymetrix’ PbA
Program. This adds significantly to our PbA Program in which we
help partners to develop novel molecular diagnostic tests that will
potentially provide solutions for directing proper treatment for
patients,” said Roger Schaller, Sr. Director of Global Business
Development for Clinical Applications at Affymetrix.
“We are very proud that PathGEN Dx, the first spin-off from GIS,
has achieved this collaboration that will significantly advance
their reach to the clinical diagnostics global market. The journey
first began in 2004 as a project in GIS, and then funded by Exploit
Technologies in 2008 to clinically validate, productize, and
develop the business strategy. This is an exciting next phase in
PathGEN DX’s entrepreneurial journey and we look forward to greater
success,” said Mr. Philip Lim, CEO of Exploit Technologies,
A*STAR’s technology transfer arm.
“The Genome Institute of Singapore is pleased to support PathGEN
Dx and look forward to incubating more startups in the future,”
said Prof. Ng Huck Hui, Acting Executive Director of GIS.
This PbA Program agreement also provides PathGEN Dx access to
Affymetrix’ international distribution network.
Dr. Christopher Wong, Founder of PathGEN Dx, added “We are
pleased to join the ranks of other PbA Program partners, such as
Roche Diagnostics and Pathwork Diagnostics in adopting the
Affymetrix technology in our IVD product development program.”
PLEASE NOTE: Affymetrix®, the Affymetrix logo, Powered by
Affymetrix, and GeneChip® are registered trademarks of Affymetrix,
Inc. All other trademarks are the property of their respective
owners.
About PathGEN Dx Pte. Ltd.
PathGEN Dx is the first spin-off company founded by scientists
from the Genome Institute of Singapore, under the Agency for
Science, Technology and Research (A*STAR), and aims to be a global
solutions provider in the research, biosurveillance, and diagnostic
markets. We conduct research and develop products for infectious
disease diagnostics, biosurveillance, and epidemiology. Our
proprietary PathGEN® PathChip Kit can efficiently detect
clinically significant pathogens and potentially novel infectious
disease threats. It can be used in private laboratories, research
institutions, contract research organizations, and pharmaceutical
companies where test results can be used to rapidly drive
laboratory research and findings into clinical applications and
interventions.
PathGEN Dx was also recently awarded a TECS POV grant from
SPRING Singapore for its research work.
For more information, please
visit http://www.pathgendx.com
About the Agency for Science, Technology and Research
(A*STAR)
The Agency for Science, Technology and Research (A*STAR) is the
lead agency for fostering world-class scientific research and
talent for a vibrant knowledge-based and innovation-driven
Singapore. A*STAR oversees 14 biomedical sciences and physical
sciences and engineering research institutes, and six consortia
& centers, located in Biopolis and Fusionopolis as well as
their immediate vicinity. A*STAR supports Singapore's key economic
clusters by providing intellectual, human and industrial capital to
its partners in industry. It also supports extramural research in
the universities, and with other local and international partners.
For more information about A*STAR, please visit
www.a-star.edu.sg.
About Affymetrix
Affymetrix technologies are used by the world's top
pharmaceutical, diagnostic, and biotechnology companies, as well as
leading academic, government, and nonprofit research institutes.
More than 26,000 peer-reviewed papers have been published citing
the technologies. Affymetrix is headquartered in Santa Clara,
Calif., and has manufacturing facilities in Santa Clara, San Diego,
Cleveland, Ohio, Singapore, and Austria. The company has about
1,180 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies" or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024